C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Purchases New Position in iShares Biotechnology ETF (NASDAQ:IBB)

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 31,475 shares of the financial services provider’s stock, valued at approximately $4,161,000. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors owned about 0.07% of iShares Biotechnology ETF as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Huntington National Bank lifted its holdings in iShares Biotechnology ETF by 17.9% during the 3rd quarter. Huntington National Bank now owns 1,054 shares of the financial services provider’s stock valued at $153,000 after purchasing an additional 160 shares during the last quarter. National Bank of Canada FI lifted its holdings in iShares Biotechnology ETF by 5.9% during the 3rd quarter. National Bank of Canada FI now owns 4,124 shares of the financial services provider’s stock valued at $600,000 after purchasing an additional 229 shares during the last quarter. Avior Wealth Management LLC lifted its holdings in iShares Biotechnology ETF by 438.2% during the 3rd quarter. Avior Wealth Management LLC now owns 3,229 shares of the financial services provider’s stock valued at $470,000 after purchasing an additional 2,629 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its stake in shares of iShares Biotechnology ETF by 32.9% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock worth $96,533,000 after acquiring an additional 164,000 shares during the last quarter. Finally, Main Management ETF Advisors LLC raised its stake in shares of iShares Biotechnology ETF by 2.5% in the third quarter. Main Management ETF Advisors LLC now owns 593,370 shares of the financial services provider’s stock worth $86,395,000 after acquiring an additional 14,535 shares during the last quarter. 62.45% of the stock is owned by institutional investors.

iShares Biotechnology ETF Stock Down 0.4 %

Shares of NASDAQ IBB opened at $136.55 on Tuesday. iShares Biotechnology ETF has a 1-year low of $123.60 and a 1-year high of $150.57. The company has a 50-day moving average of $135.62 and a two-hundred day moving average of $140.86.

iShares Biotechnology ETF Cuts Dividend

The business also recently announced a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were paid a $0.0624 dividend. The ex-dividend date was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.